Patients included in the trial had HR+/HER2– metastatic breast cancer, were 18 years or older, and started index treatment ...

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...

Basel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for ...

Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...

Winrevair was approved to treat PAH WHO Group 1 in the United States in March based on data from the STELLAR study.

Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a broad population. The EC has approved Kisqali in combination with an aromatase ...

Basel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone ...